Vaccines for birch pollen allergy based on genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1

Background We have recently engineered recombinant derivatives of the major birch pollen allergen Bet v 1 (rBet v 1 fragments and trimer) with strongly reduced allergenic activity.

[1]  R. Valenta,et al.  Prevention of allergen‐specific IgE production and suppression of an established Th2‐type response by immunization with DNA encoding hypoallergenic allergen derivatives of Bet v 1, the major birch‐pollen allergen , 2003, European Journal of Immunology.

[2]  R. Valenta,et al.  From allergen structure to new forms of allergen-specific immunotherapy. , 2002, Current opinion in immunology.

[3]  R. Valenta.  The future of antigen-specific immunotherapy of allergy , 2002, Nature Reviews Immunology.

[4]  P. Hufnagl,et al.  Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen, Bet v 1 , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[5]  H. Malling,et al.  Safety of allergen‐specific immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic side‐effects during induction treatment , 2000, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[6]  Oster,et al.  Comparison of genetically engineered hypoallergenic rBet v 1 derivatives with rBet v 1 wild‐type by skin prick and intradermal testing: results obtained in a French population , 2000, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[7]  R. Valenta,et al.  Comparison of inflammatory responses to genetically engineered hypoallergenic derivatives of the major birch pollen allergen bet v 1 and to recombinant bet v 1 wild type in skin chamber fluids collected from birch pollen-allergic patients. , 2000, The Journal of allergy and clinical immunology.

[8]  R. V. van Neerven,et al.  Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation. , 1999, Journal of immunology.

[9]  Niederberger,et al.  The recombinant allergen‐based concept of component‐resolved diagnostics and immunotherapy (CRD and CRIT) , 1999, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[10]  P. Bhalla,et al.  Genetically Engineered Plant Allergens with Reduced Anaphylactic Activity , 1999, International Archives of Allergy and Immunology.

[11]  J. Lidholm,et al.  Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy , 1999, European journal of immunology.

[12]  Asero.  Effects of birch pollen‐specific immunotherapy on apple allergy in birch pollen‐hypersensitive patients , 1998, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[13]  J Bousquet,et al.  Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. , 1998, The Journal of allergy and clinical immunology.

[14]  R. Valenta,et al.  Recombinant birch pollen allergens (rBet v 1 and rBet v 2) contain most of the IgE epitopes present in birch, alder, hornbeam, hazel, and oak pollen: a quantitative IgE inhibition study with sera from different populations. , 1998, The Journal of allergy and clinical immunology.

[15]  S. Durham,et al.  Immunologic changes associated with allergen immunotherapy. , 1998, The Journal of allergy and clinical immunology.

[16]  R. Valenta,et al.  Immunization with purified natural and recombinant allergens induces mouse IgG1 antibodies that recognize similar epitopes as human IgE and inhibit the human IgE-allergen interaction and allergen-induced basophil degranulation. , 1998, Journal of immunology.

[17]  G. Casari,et al.  Modulation of IgE reactivity of allergens by site‐directed mutagenesis: potential use of hypoallergenic variants for immunotherapy , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  A. Mori,et al.  Engineering of the major house dust mite allergen Der f 2 for allergen-specific immunotherapy , 1997, Nature Biotechnology.

[19]  R. Valenta,et al.  Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy. , 1997, The Journal of clinical investigation.

[20]  K. Hoffmann‐Sommergruber,et al.  High-level expression and purification of the major birch pollen allergen, Bet v 1. , 1997, Protein expression and purification.

[21]  J. Banchereau,et al.  Human IgG monoclonal antibodies that modulate the binding of specific IgE to birch pollen Bet v 1. , 1996, Journal of immunology.

[22]  M. Chapman,et al.  Reduction in IgE binding to allergen variants generated by site-directed mutagenesis: contribution of disulfide bonds to the antigenic structure of the major house dust mite allergen Der p 2. , 1996, Molecular immunology.

[23]  L. Jäger,et al.  Effect of hyposensitization for tree pollinosis on associated apple allergy. , 1995, Journal of investigational allergology & clinical immunology.

[24]  R. Valenta,et al.  Recombinant allergens for immunoblot diagnosis of tree-pollen allergy. , 1991, The Journal of allergy and clinical immunology.

[25]  R. Valenta,et al.  The gene coding for the major birch pollen allergen Betv1, is highly homologous to a pea disease resistance response gene. , 1989, The EMBO journal.

[26]  H. Ipsen,et al.  Immunotherapy with partially purified and standardized tree pollen extracts , 1988, Allergy.

[27]  D. Marsh,et al.  Standardized extracts modified allergens-allergoids , 1987, Clinical reviews in allergy.

[28]  S. Fling,et al.  Peptide and protein molecular weight determination by electrophoresis using a high-molarity tris buffer system without urea. , 1986, Analytical biochemistry.

[29]  J. Weiler,et al.  Clinical and immunologic evaluation of glutaraldehyde-modified tyrosine-adsorbed short ragweed extract: a double-blind, placebo-controlled trial. , 1981, The Journal of allergy and clinical immunology.

[30]  H. Towbin,et al.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[31]  A. Sehon,et al.  Abrogation of reaginic antibodies with modified allergens , 1977, Nature.

[32]  L. Lichtenstein,et al.  Studies on "allergoids" prepared from naturally occurring allergens. I. Assay of allergenicity and antigenicity of formalinized rye group I component. , 1970, Immunology.

[33]  Oliver H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[34]  K. Hoffmann‐Sommergruber,et al.  Quantitative IgE inhibition experiments with purified recombinant allergens indicate pollen-derived allergens as the sensitizing agents responsible for many forms of plant food allergy. , 2000, The Journal of allergy and clinical immunology.

[35]  P. Briza,et al.  Modulation of IgE-binding properties of tree pollen allergens by site-directed mutagenesis. , 1996, Advances in experimental medicine and biology.

[36]  M. Chapman,et al.  Reduction of IgE antibody binding to rDer p 2 variants generated by site-directed mutagenesis. , 1996, Advances in experimental medicine and biology.